Publication
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (12)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 12
- cancerMalignant Neoplasmcivic_curation1.00
- cancerUrothelial Carcinomacivic_curation1.00
- drugErdafitinibcivic_curation1.00
- drugFutibatinibcivic_curation1.00
- geneFGFR3civic_curation1.00
- genePIK3CAcivic_curation1.00
- geneTACC3civic_curation1.00
- variantFGFR3 N540Kcivic_curation1.00
- variantFGFR3 S249Ccivic_curation1.00
- variantFGFR3 Y373Ccivic_curation1.00
- variantPIK3CA E545Kcivic_curation1.00
- variantTACC3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37377403
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR3 N540K + TACC3 FusionTACC3FGFR31 | ||||||||
| Erdafitinib + FutibatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID12706Ba/F3 cells expressing the FGFR3::TACC3 fusion with or without the N540K mutation were treated with multiple FGFR inhibitors, including erdafitinib and futibatinib. In parental Ba/F3 cells, the IC50 v… (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC | civic |
| FGFR3 N540K + FGFR3 Y373C1 | ||||||||
| Erdafitinib + FutibatinibSequential | Urothelial Carcinoma | Predictive | C | Supports Resistance | 4 | accepted | EID12704In this study of patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors, longitudinal ctDNA analysis identified emergent FGFR3 kinase domain mutations at disease progres… (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC | civic |
| FGFR3 N540K + FGFR3 S249C + PIK3CA E545KPIK3CAFGFR31 | ||||||||
| Erdafitinib | Urothelial Carcinoma | Predictive | C | Supports Resistance | 4 | accepted | EID12703In this study of 21 patients with FGFR-driven urothelial carcinoma treated with selective FGFR inhibitors (including erdafitinib), post-progression molecular analyses (tissue and/or ctDNA sequencing) … (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC | civic |
| FGFR3 N540K1 | ||||||||
| (functional) | —UNRESOLVED | Functional | D | Supports Gain Of Function | 2 | accepted | EID12705Western blots were performed on Ba/F3 cells expressing driver fusion FGFR3::TACC3 and FGFR3::TACC3 plus FGFR3 N540K. In the FGFR3::TACC3 plus FGFR3 N540K cells, levels of phosphoylated FGFR (p-FGFR), … (full text at CIViC) PMID 37377403 · Facchinetti et al., 2023 · Open in CIViC | civic |